An interventional study of Intensive Case Management and Treatment as Usual (TAU) in Substance Use Disorders, sponsored by Psychiatric Services Aargau AG. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Psychiatric Services Aargau AG · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Substance-Related Disorders with a site in Switzerland — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Switzerland.
Among the 27 studies in Substance-Related Disorders with a site in Switzerland, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 27th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →6 of the 27 studies in Substance-Related Disorders with a site in Switzerland are open now. Recruiting first, the newest first:
NORCE Norwegian Research Centre AS · Sites in Switzerland, Austria, Israel and 5 more countries
Ages 18+
Louise Penzenstadler · Sites in Switzerland
Ages 18+
Susanne Walitza · Sites in Switzerland
Ages 8–18 · Healthy volunteers
Louise Penzenstadler · Sites in Switzerland
Ages 18+
Prof. Dagmar M. Haller · Sites in Switzerland
Ages 14–24 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 28 across the 23 interventional studies, 45 across the 4 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 27 have an industry lead sponsor. The 10 most frequent:
Psychiatric Services Aargau AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Psychiatric Services Aargau AG has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Substance-Related Disorders with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.
Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).
Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.
In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:
Sex and gender will be treated as potential covariates and will be considered in the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
receives ICM immediately
Other: Intensive Case Management
Same as Experimental, only with 6-Month TAU-Waiting List before ICM
Other: Treatment as Usual (TAU)
Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement: 1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients. 2. Relationship continuity: Establishing an empathetic \& constant presence, breaking down barriers, creating a trustful, stable relationship.
TAU will take place for 6 months before starting with ICM
Number of Inpatient Admissions (Health Service utilisation)
Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
WHOQoL-BREF
Quality of Life
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Social Functioning Questionnaire
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
ASSIST
Substance use characteristics
Time frame: 6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Continuity of Care describes timeframes of the health services used outside the ward.
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Retention describes the voluntary staying of patients in the ICM treatment
Time frame: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care
Time frame: 6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)
Time frame: 6 Months (exploratory), 24 months (exploratory)
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 36 months is close to that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Psychiatric Services Aargau AG